Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates.
Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates.
复制标题
乳腺癌肝转移：超声引导下的经皮射频消融——中期和长期生存率。
DOI：
10.1148/radiol.2533081968
复制
发表时间：
2009-12
期刊：
影响因子：
19.7
通讯作者：
Lee FT Jr
中科院分区：
文献类型：
--
作者：
Meloni MF;Andreano A;Laeseke PF;Livraghi T;Sironi S;Lee FT Jr
回顾性评估接受经皮超声（US）引导射频（RF）消融的乳腺癌肝转移患者的局部控制和中长期生存率。本研究得到了医院伦理委员会的批准，所有患者均提供了书面知情同意书。射频消融用于治疗52名女性患者（中位年龄55岁）的87个乳腺癌肝转移灶（平均直径2.5 cm）。入选标准如下：少于5个肿瘤，最大肿瘤直径为5 cm或更小，疾病局限于肝脏或经药物治疗稳定。50例患者中有45例（90%）既往接受过化疗、激素治疗或两者兼而有之，对治疗无反应或反应不完全。进行造影剂增强计算机断层扫描和US以评价并发症和技术成功，并评估随访期间的局部肿瘤进展。采用Kaplan-Meier法评估生存率，并采用对数秩检验比较各组结果。考克斯回归分析用于评估影响生存率的独立预后因素。97%的肿瘤完全坏死。发生2例（4%）轻微并发症。从诊断肝转移和射频消融到随访的中位时间分别为37.2和19.1个月。25%的患者发生局部肿瘤进展。53%的患者发生了新的肝内转移。从第一次射频消融开始，总体中位生存时间和5年生存率分别为29.9个月和27%。从第一次肝转移被诊断的时间，总的中位生存时间为42个月，5年生存率为32%。肿瘤直径大于等于2.5 cm的患者比肿瘤直径小于2.5 cm的患者预后更差（风险比为2.1）。选定的乳腺癌肝转移患者接受射频消融治疗的生存率与文献中报告的手术或激光消融治疗的生存率相当。
To retrospectively assess the local control and intermediate- and long-term survival of patients with liver metastases from breast cancer who have undergone percutaneous ultrasonography (US)-guided radiofrequency (RF) ablation. This study was approved by the hospital ethics committee, and all patients provided written informed consent. RF ablation was used to treat 87 breast cancer liver metastases (mean diameter, 2.5 cm) in 52 female patients (median age, 55 years). Inclusion criteria were as follows: fewer than five tumors, maximum tumor diameter of 5 cm or smaller, and disease either confined to the liver or stable with medical therapy. Forty-five (90%) of 50 patients had previously undergone chemotherapy, hormonal therapy, or both, and had no response or an incomplete response to the treatment. Contrast material–enhanced computed tomography and US were performed to evaluate complications and technical success and to assess for local tumor progression during follow-up. The Kaplan-Meier method was used to assess survival, and results were compared between groups with a log-rank test. Cox regression analysis was used to assess independent prognostic factors that affected survival. Complete tumor necrosis was achieved in 97% of tumors. Two (4%) minor complications occurred. Median time to follow-up from diagnosis of liver metastasis and from RF ablation was 37.2 and 19.1 months, respectively. Local tumor progression occurred in 25% of patients. New intrahepatic metastases developed in 53% of patients. From the time of first RF ablation, overall median survival time and 5-year survival rate were 29.9 months and 27%, respectively. From the time the first liver metastasis was diagnosed, overall median survival time was 42 months, and the 5-year survival rate was 32%. Patients with tumors 2.5 cm in diameter or larger had a worse prognosis (hazard ratio, 2.1) than did patients with tumors smaller than 2.5 cm in diameter. Survival rates in selected patients with breast cancer liver metastases treated with RF ablation are comparable to those reported in the literature that were achieved with surgery or laser ablation.
登录
查看更多内容
DOI：
10.1102/1470-7330.2005.0015
发表时间：
2005-09-21
期刊：
Cancer imaging : the official publication of the International Cancer Imaging Society
影响因子：
--
作者：
Gillams, A R
通讯作者：
Gillams, A R
DOI：
10.1016/j.jvir.2006.10.014
发表时间：
2007-01-01
影响因子：
2.9
作者：
Gunabushanam, Gowthaman;Sharma, Sanjay;Bhatnagar, Sushma
通讯作者：
Bhatnagar, Sushma
影响因子：
17.3
作者：
HOE, AL;ROYLE, GT;TAYLOR, I
通讯作者：
TAYLOR, I
影响因子：
3.7
作者：
Caralt, Mireia;Bilbao, Itxarone;Charco, Ramon
通讯作者：
Charco, Ramon
影响因子：
50.5
作者：
Ferlay, J.;Autier, P.;Boyle, P.
通讯作者：
Boyle, P.